Clinical Trial Update: Using GM-CSF as a Host Directed Therapeutic Against COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating GM-CSF as a host-directed therapy for COVID-19 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Singapore General Hospital | Conditions: COVID, Sars-CoV2 | Phase 2 | Status: COMPLETED